(Q44516164)

3 December 2017

title

Infliximab in the treatment of refractory posterior uveitis (English)

1 reference

3 December 2017

1 reference

Annie Joseph

1

1 reference

3 December 2017

Dev Raj

2

1 reference

3 December 2017

Harminder S Dua

3

1 reference

3 December 2017

Pauline T Powell

4

1 reference

3 December 2017

Peter C Lanyon

5

1 reference

3 December 2017

Richard J Powell

6

1 reference

3 December 2017

publication date

1 July 2003

1 reference

3 December 2017

1 reference

3 December 2017

volume

110

1 reference

3 December 2017

issue

7

1 reference

3 December 2017

page(s)

1449-1453

1 reference

Autoimmunity and autoimmune disease of the eye.

3 December 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Immunopathogenic mechanisms in intraocular inflammation.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Immunopathology of the noninfectious posterior and intermediate uveitides

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Cytokine gene expression in different strains of mice with endotoxin-induced uveitis (EIU).

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Aqueous Humor and Serum Tumor Necrosis Factor-α in Clinical Uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Etanercept therapy in children with treatment-resistant uveitis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Effect of infliximab on sight-threatening panuveitis in Behçet's disease.

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Therapeutic efficacy of multiple intravenous infusions of anti-tumor necrosis factor alpha monoclonal antibody combined with low-dose weekly methotrexate in rheumatoid arthritis

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Infliximab (chimeric anti-tumour necrosis factor alpha monoclonal antibody) versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Effect of infliximab on threatening panuveitis in Behçet's disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Differential efficacy of tumor necrosis factor inhibition in the management of inflammatory eye disease and associated rheumatic disease

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Tuberculosis associated with infliximab, a tumor necrosis factor alpha-neutralizing agent

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

Tuberculosis and treatment with infliximab

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

1 reference

7 January 2021

Cytokines in human intraocular inflammation

1 reference

https://api.crossref.org/works/10.1016%2FS0161-6420%2803%2900406-8

7 January 2021

10.1016/S0161-6420(03)00406-8

Identifiers

DOI

1 reference

3 December 2017

1 reference